NCT01281189

Who might be able to join this trial:

• You must be between 18 and 80 years old at the start of the trial.
• You must have been diagnosed with ALS, either the sporadic (no family history) or familial (runs in the family) type.
• Your first ALS symptoms must have started within the last 24 months before joining the trial.
• Your ALS diagnosis must meet certain recognised medical standards for a possible, probable, or definite diagnosis (confirm with trial site).
• Your lung breathing capacity when sitting upright must be 65% or more of what is considered normal.
• You may or may not be taking the ALS medication Riluzole, but if you are currently taking it, you must have been on the same dose for at least 60 days; if you recently stopped taking it, you must have stopped at least 30 days ago.
• You must be able to swallow tablets when you enter the study.

Who may not be able to join:

• You have another serious medical illness alongside ALS.
• Your routine blood or other lab test results show significant abnormalities.
• You are currently pregnant or breastfeeding.
• You have previously taken a drug called dexpramipexole.
• You are currently taking a medication called pramipexole or any similar type of drug known as a dopamine agonist (confirm with trial site if unsure about your current medications).

Important: Always verify eligibility with the trial site directly before applying.